Modification of Chronic Inflammation by Inhaled Carbon Monoxide in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD)
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Primary Purpose: Treatment
|Official Title:||Modification of Chronic Inflammation by Inhaled Carbon Monoxide in Patients With Stable COPD|
- percentage of neutrophils in induced sputum
- methacholine provocation threshold
- exhaled CO/NO
- FEV1, FVC, RAW, sgaw
- inflammatory parameters in sputum and blood
- 8-isoprostane in exhaled breath
|Study Start Date:||January 2005|
|Estimated Study Completion Date:||March 2006|
COPD is characterised by a chronic pulmonary inflammation and a shifted oxidant/antioxidant balance. The main cause of this inflammation is smoking. After smoking cessation, this inflammation and shifted oxidant/antioxidant balance continues. This causes an increased deterioration of lung function compared to healthy persons of matching age.
The ongoing inflammation appears to be relatively insensitive to corticosteroid therapy.
Until now, there is no therapy for this inflammation. Both in vitro and in vivo studies show that carbon monoxide has, besides an antioxidant capacity, anti-inflammatory properties. The aim of this trial is to study whether the inflammation can be reduced by inhalation of carbon monoxide.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00122694
|University Medical Center Groningen, Department of Pulmonary Diseases|
|Groningen, Netherlands, 9700RB|
|Principal Investigator:||H AM Kerstjens, Prof., MD, PhD||University Medical Center Groningen, Department of Pulmonary Diseases|